[Research findings on 50 patients with panmyelopathy].
D045930:Anabolic Agents / Q000627:therapeutic use; D000741:Anemia, Aplastic / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000628:therapy; D001772:Blood Cell Count; D001803:Blood Transfusion; D002701:Chloramphenicol / Q000009:adverse effects; D004912:Erythrocytes; D005260:Female; D005500:Follow-Up Studies; D005860:Germany, West; D005938:Glucocorticoids / Q000627:therapeutic use; D006490:Hemostatics / Q000627:therapeutic use; D006505:Hepatitis / Q000150:complications; D006801:Humans; D008297:Male; D009107:Mumps / Q000150:complications; D010653:Phenylbutazone / Q000009:adverse effects; D010949:Plasma; D013449:Sulfonamides / Q000009:adverse effects; D013752:Tetracycline / Q000009:adverse effects; D013997:Time Factors; D014376:Tuberculosis / Q000150:complications
D045930:Anabolic Agents; D005938:Glucocorticoids; D006490:Hemostatics; D013449:Sulfonamides; D002701:Chloramphenicol; D013752:Tetracycline; D010653:Phenylbutazone
Untersuchungsergebnisse bei 50 Patienten mit Panmyelopathie.